Logo Logo
Hilfe
Hilfe
Switch Language to English

Westhofen, Thilo ORCID logoORCID: https://orcid.org/0000-0003-3812-5485; Frank, Kerstin; Buchner, Alexander ORCID logoORCID: https://orcid.org/0000-0001-7895-7070; Becker, Armin; Eismann, Lennert; Rodler, Severin ORCID logoORCID: https://orcid.org/0000-0002-7600-6535; Aydogdu, Can; Berg, Elena; Jokisch, Friedrich; Kazmierczak, Philipp M.; Stief, Christian G. ORCID logoORCID: https://orcid.org/0000-0003-3291-9460 und Kretschmer, Alexander (22. Juli 2024): The impact of preoperative 5-alpha reductase inhibitors on functional outcomes and health-related quality of life following radical prostatectomy – A propensity score matched longitudinal study. In: World Journal of Urology, Bd. 42, 432 [PDF, 1MB]

Abstract

Objectives

While the impact of treatment with 5-alpha Reductase Inhibitors (5-ARI) on the risk of cancer-related mortality in men with prostate cancer (PC) has been extensively studied, little is known about the impact of preoperative 5-ARI use on patient-reported outcomes (PROs) following radical prostatectomy (RP).

Methods

Within our prospectively maintained institutional database of 5899 patients treated with RP for PC (2008– 2021), 99 patients with preoperative 5-ARI therapy were identified. A 1:4 propensity-score matched analysis of 442 men (n = 90 5-ARI, n = 352 no 5-ARI) was conducted. Primary endpoint was continence recovery using daily pad usage and ICIQ-SF. Health-related quality of life (HRQOL) was assessed using the validated EORTC QLQ-C30 and PR25 questionnaires. Multivariable Cox-regression-models tested the effect of preoperative 5-ARI treatment on continence-recovery (p < 0.05).

Results

Patients were followed up perioperatively, followed by annual assessments up to 60mo postoperatively. Preoperative mean ICIQ-SF score (2.2 vs. 0.9) was significantly higher in the 5-ARI cohort (p = 0.006). 24mo postoperatively, 68.6% (no 5-ARI) vs. 55.7% (5-ARI) had full continence recovery (p = 0.002). Multivariable Cox regression analysis, revealed preoperative 5-ARI treatment as an independent predictor for impaired continence recovery (HR 0.50, 95% CI 0.27–0.94, p = 0.03) In line, general HRQOL was significantly higher for patients without 5-ARI only up to 24mo postoperatively (70.6 vs. 61.2, p = 0.045). There was no significant impact of preoperative 5-ARI treatment on erectile function, biochemical recurrence-free survival and metastasis-free survival.

Conclusions

Pre-RP 5-ARI treatment was associated with impaired continence outcomes starting 24mo postoperatively, suggesting that preoperative 5-ARI treatment can impair the long-term urinary function recovery following RP.

Dokument bearbeiten Dokument bearbeiten